The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

The use of the glycoprotein (GP) IIb/IIIa receptor antagonist Abciximab has over the years become an important part of the anticoagulant regimen in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Abciximab is a potent inhibitor of platelet aggregation and thrombu...

Descripción completa

Detalles Bibliográficos
Autores principales: Iversen, Allan, Galatius, Søren, Jensen, Jan S
Formato: Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801861/
https://www.ncbi.nlm.nih.gov/pubmed/20066137
http://dx.doi.org/10.2174/157340308786349480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801861/
https://www.ncbi.nlm.nih.gov/pubmed/20066137
http://dx.doi.org/10.2174/157340308786349480

Ejemplares similares